Imprimis Pharmaceuticals Announces First Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St set for higher open after retail earnings; Moderna soars
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Target raises full-year sales forecast amid ongoing turnaround drive
- Tech selloff weighs down Wall Street as bond yields climb
- Marvell issues Google warrant tied to custom chip deal
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Imprimis Pharma (IMMY) Reports Q1 Revenues Above Estimates
May 15, 2018 4:02 PM EDTImprimis Pharma (NASDAQ: IMMY) reported Q1 EPS of $, versus $0.00 reported last year. Revenue for the quarter came in at $8.9 million versus the consensus estimate of $6.86 million.
Notable Highlights:
Revenue of $8.9 million, up 45% year-over-yearGross ophthalmology-related revenue of $7.0 million, up 91%... More